title: Comparison of active and passive targeting of docetaxel for prostate cancer therapy by HPMA copolymer-RGDfK conjugates.
abstract: N-(2-Hydroxypropyl)methacrylamide (HPMA) copolymer-docetaxel-RGDfK conjugate was synthesized, characterized, and evaluated in vitro and in vivo in comparison with untargeted low and high molecular weight HPMA copolymer-docetaxel conjugates. The targeted conjugate was designed to have a hydrodynamic diameter below renal threshold to allow elimination post treatment. All conjugates demonstrated the ability to inhibit the growth of DU145 and PC3 human prostate cancer cells and the HUVEC at low nanomolar concentrations. The targeted conjugate showed active binding to α(v)β(3) integrins in both HUVEC and DU145 cells, whereas the untargeted conjugate demonstrated no evidence of specific binding. Efficacy at two concentrations (20 mg/kg and 40 mg/kg) was evaluated in nu/nu mice bearing DU145 tumor xenografts treated with a single dose of conjugates and compared with controls. RGDfK targeted and high molecular weight nontargeted conjugates exhibited the highest antitumor efficacy as evaluated by tumor regression. These results demonstrate that α(v)β(3) integrin targeted polymeric conjugates with improved water solubility, reduced toxicity and ease of elimination post treatment in vivo are promising candidates for prostate cancer therapy.
authors: Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, Utah 84108, USA.
authors: Abhijit
authors: A
authors: Ray
authors: Nate
authors: N
authors: Larson
authors: Daniel B
authors: DB
authors: Pike
authors: Michele
authors: M
authors: Grüner
authors: Sachin
authors: S
authors: Naik
authors: Hillevi
authors: H
authors: Bauer
authors: Alexander
authors: A
authors: Malugin
authors: Khaled
authors: K
authors: Greish
authors: Hamidreza
authors: H
authors: Ghandehari
references: Nat Rev Cancer. 2002 Feb;2(2):83-90
references: 12635171
references: Adv Drug Deliv Rev. 2010 Feb 17;62(2):122-49
references: 19919846
references: Nucl Med Biol. 2004 Jan;31(1):11-9
references: 14741566
references: Cancer Chemother Rep. 1966 May;50(4):219-44
references: 4957125
references: Nat Methods. 2010 Aug;7(8):655-60
references: 20581828
references: Nature. 2000 Sep 14;407(6801):242-8
references: 11001067
references: J Natl Cancer Inst. 1991 Feb 20;83(4):288-91
references: 1671606
references: Biomaterials. 1980 Oct;1(4):199-204
references: 7470574
references: Br J Cancer. 2003 Dec;89 Suppl 3:S9-S15
references: 14661041
references: J Control Release. 2000 Mar 1;65(1-2):271-84
references: 10699287
references: Cancer. 2003 Oct 15;98(8):1627-34
references: 14534878
references: J Control Release. 2011 May 10;151(3):263-70
references: 21223983
references: Cancer Res. 1996 Sep 15;56(18):4264-6
references: 8797602
references: Mol Pharm. 2009 Nov-Dec;6(6):1836-47
references: 19743884
references: Pharm Res. 2009 May;26(5):1121-9
references: 19160028
references: Science. 2010 May 21;328(5981):1031-5
references: 20378772
references: Cancer. 2002 Mar 1;94(5):1457-65
references: 11920502
references: J Natl Cancer Inst. 2006 Apr 19;98(8):516-21
references: 16622120
references: Cancer Res. 1994 Sep 1;54(17):4564-8
references: 8062241
references: Int J Cancer. 2002 Dec 10;102(5):469-75
references: 12432548
references: Ann Oncol. 2001 Sep;12(9):1273-9
references: 11697840
references: Biotechnology (N Y). 1995 Mar;13(3):265-70
references: 9634769
references: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references: 19474385
references: Eur J Pharm Biopharm. 2000 Jul;50(1):61-81
references: 10840193
references: J Pharm Sci. 2006 Jun;95(6):1177-95
references: 16639719
references: Jpn J Cancer Res. 1998 Mar;89(3):307-14
references: 9600125
references: Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005247
references: 17054249
references: J Natl Cancer Inst. 1979 Feb;62(2):387-95
references: 283271
references: Cancer Res. 1987 Jun 15;47(12):3039-51
references: 3555767
references: Science. 2005 Jan 7;307(5706):58-62
references: 15637262
references: J Drug Target. 2004 Jun;12(5):257-64
references: 15512776
references: Curr Gene Ther. 2009 Oct;9(5):422-7
references: 19860656
references: Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
references: 2946403
references: J Control Release. 2000 Feb 14;64(1-3):63-79
references: 10640646
references: Adv Genet. 2010;69:65-82
references: 20807602
references: FASEB J. 2008 Mar;22(3):659-61
references: 17942826
references: N Engl J Med. 2004 Oct 7;351(15):1513-20
references: 15470214
references: Semin Oncol. 1999 Oct;26(5 Suppl 17):19-23
references: 10604264
references: Nat Rev Cancer. 2002 Feb;2(2):91-100
references: 12635172
references: Adv Drug Deliv Rev. 2010 Feb 17;62(2):167-83
references: 19951733
references: Cancer Res. 1992 Sep 15;52(18):5110-4
references: 1516068
references: Cancer Res. 1990 Aug 1;50(15):4478-84
references: 2369726
references: Semin Oncol. 2001 Aug;28(4 Suppl 15):8-15
references: 11685723
references: Pharm Res. 1990 Apr;7(4):339-46
references: 1694582
references: N Engl J Med. 2004 Oct 7;351(15):1502-12
references: 15470213
references: J Control Release. 2006 Aug 28;114(2):175-83
references: 16889865
references: Semin Oncol. 1999 Oct;26(5 Suppl 17):14-8
references: 10604263
references: Appl Radiat Isot. 2004 Nov;61(5):963-7
references: 15308176
references: Lancet Oncol. 2005 Apr;6(4):229-39
references: 15811618
references: Curr Pharm Des. 2006;12(22):2723-47
references: 16918408
references: Anticancer Drugs. 2007 Feb;18(2):95-103
references: 17159596
references: Nat Clin Pract Urol. 2008 Sep;5(9):486-93
references: 18769375
references: Nat Biotechnol. 1997 Jun;15(6):542-6
references: 9181576
references: Pharm Res. 1996 Jun;13(6):820-31
references: 8792417
references: Mol Cancer Ther. 2002 Nov;1(13):1191-200
references: 12479700
references: Nat Rev Clin Oncol. 2010 Nov;7(11):653-64
references: 20838415
references: Tumori. 2006 Nov-Dec;92(6):542-4
references: 17260498
references: Nat Rev Drug Discov. 2003 May;2(5):347-60
references: 12750738
references: J Clin Oncol. 2001 May 1;19(9):2509-16
references: 11331330
references: Pharm Res. 2009 Jun;26(6):1407-18
references: 19225872
references: Adv Drug Deliv Rev. 2005 Feb 28;57(4):609-36
references: 15722167
references: Biomaterials. 1990 Sep;11(7):455-64
references: 2242394
references: Biomaterials. 1989 Jul;10(5):335-42
references: 2765631
references: Nature. 2000 Sep 14;407(6801):249-57
references: 11001068
references: Rev Urol. 2003;5 Suppl 2:S14-21
references: 16986041
references: Cancer Res. 1992 Dec 1;52(23):6553-60
references: 1384965
references: J Control Release. 2003 Aug 28;91(1-2):115-22
references: 12932643